Navigation Links
Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,,,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,,,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,,,Disease

ficantly lower than the rate in the bare metal stent arm of the ARTS I Study (1.3 percent versus 7.1 percent, respectively; p = 0.018). Three-year stent thrombosis comparisons with the BMS arm were not possible, as the ARTS I Study did not track stent thrombosis rates beyond 30 days. The cumulative rates of definite stent thrombosis for the CYPHER(R) Stent at three-year follow-up in the overall ARTS II Study patient population was 3.3 percent. Investigators did not find significant differences in the stent thrombosis rates between the ARTS II diabetic and non-diabetic patients using any of the ARC definitions.

The CYPHER(R) Stent does not have an approved indication in the United States for diabetic patients or patients with multivessel coronary disease.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at




Page: 1 2 3 4

Related medicine technology :

1. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
8. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
9. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
10. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
Post Your Comments:
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, ... awarded CSL Behring its 2015 Corporate Leadership Award ... advancing science and improving the care of the bleeding disorders ... CEO and Managing Director, CSL Limited, during the NHF Annual ... on May 21. "The National Hemophilia Foundation is ...
(Date:5/22/2015)... According to a new market ... Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020", published by ... reach $736.85 Million by 2020 from $452.36 Million in ... Browse 71 market data Tables and 90 Figures ...
(Date:5/22/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3rthk2/latest ) ... Regulations on Pharmaceutical International Multi-Center Clinical Trials in ... This is first time in history, Chinese pharmaceutical ... clinical trials of drugs in China ... on March 1, 2015. The guidance provides an ...
Breaking Medicine Technology:National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... achieve undetectable HCV RNA levels following 4 weeks of, treatment with R7128 ... ... - Conference Call Scheduled for 4:00PM ET Today ... announces the preliminary results of a 4-week Phase 1,clinical trial to evaluate ...
... Calif., Jan. 7 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... drug designation from the U.S. Food and Drug ... treatment of recurrent acute,repetitive seizures. In December 2007, ... II clinical trial of JZP-8., JZP-8 is ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate 2Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate 3
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Rehabilitation Center, 557 N. Washington St., Janesville, will host ... 5:30-6:30 pm. , The 8-week clinic is lead by ... BSN, who will offer training that encompasses a warm-up, ... and show selection and weekly training plans. , The ...
(Date:5/22/2015)... May 22, 2015 Pioneer Millworks, the ... the forefront of designing with reclaimed wood, introducing their ... Los Angeles, California. Their newest offerings, Vat 35, ... surface and color to America's largest design event. , ... at each show, anxious to see and feel the ...
(Date:5/22/2015)... 2015 Hundreds of federal Xarelto ... individuals who allegedly experienced serious internal bleeding and ... move forward in the U.S. District Court, Eastern ... dated May 4, 2015, the Court has established ... stored information. Among other things, the Order sets ...
(Date:5/22/2015)... 22, 2015 Hands On HealthCare Massage ... 2015, the Annual One Day Sale on Massage ... On HCMT offers drastically reduced certificates one day a year. ... enough sessions, through what used to be the slowest time ... the community as well. This once a year occurrence has ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Coordinating ... a difficult process. Historically providers have not been ... payers. Starting in 2015, Medicare has paved the ... activities. Thanks to the launch of Oculus ... and health systems using the platform will now ...
Breaking Medicine News(10 mins):Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4
... Illuminating the molecular details of normal sperm development, demonstrating ... boy sterile, and pursuing ways to restore fertility have ... University of Texas M. D. Anderson Cancer Center. , ... of Experimental Radiation Oncology, will be inducted as a ...
... for Introducing Key Legislation WASHINGTON, Feb. 13 ... applauded the efforts of Senator Jay Rockefeller (D-WV), ... and Representative Bob Filner, Chairman of the House ... amend Section 7422 of Title 38, expanding the ...
... and tested a synthetic atherosclerosis drug that can reduce ... the side-effect of fatty liver disease (which leads to ... results of this study in mice could lead to ... prevent atherosclerosis. , Targets of this drug, called DMHCA, ...
... to be part of the shared evolutionary past of ... abstractions that apparently takes human math to a higher ... of psychology and neuroscience at Duke University, studies how ... numbers without using language. She,s looking for the brain ...
... of Michigan supports physical activity and nutrition programs for ... 16,600 Michigan children and their local communities will get ... physical activities and to learn to eat healthily, through ... join youngsters like those at Detroit,s Maybury Elementary School ...
... Weight Watchers International, Inc. (NYSE: WTW ... analysts on Thursday, March 5th in New York City. ... overview of the Company,s operations and initiatives.Presentations are expected ... approximately 12:00 p.m. ET. The event will be webcast ...
Cached Medicine News:Health News:Male fertility expert Marvin Meistrich elected AAAS Fellow 2Health News:Male fertility expert Marvin Meistrich elected AAAS Fellow 3Health News:Veterans' Affairs Employee Union Urges Congress to Strengthen Collective Bargaining Rights at VA Hospitals 2Health News:Pre-verbal number sense common to monkeys, babies, college kids 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 3Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 4Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 5Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 6Health News:Weight Watchers to Host Investor Meeting 2
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
DS 100, double side an economical, easy-to-use instrument for the automatic staining in histology and cytology....
Cholesterol, Total. An automated analyzer test kits....
For the quantitative determination of total cholesterol in serum....
Medicine Products: